Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 400 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; hypromellose; microcrystalline cellulose; magnesium stearate; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amisulpride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amisulpride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amisulpride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; peg-40 stearate; lactose monohydrate; titanium dioxide; hypromellose; microcrystalline cellulose - the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - amisulpride 200 mg - tablet - 200 mg - amisulpride 200 mg - amisulpride

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amisulpride 400mg;   - film coated tablet - 400 mg - active: amisulpride 400mg   excipient: basic butylated methacrylate copolymer isopropyl alcohol lactose monohydrate macrogol 6000 magnesium stearate   methylcellulose microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amisulpride 100mg;   - tablet - 100 mg - active: amisulpride 100mg   excipient: lactose monohydrate magnesium stearate methylcellulose microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amisulpride 50mg;   - tablet - 50 mg - active: amisulpride 50mg   excipient: lactose monohydrate magnesium stearate methylcellulose microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride -